Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.30 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.30 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinimide SCHEMBL3262638 | 0.90 | CRBN (0.65) | CRBNNPC1MAPK13MAPK12MAPK11 | |
| Succinimide SCHEMBL28381869 | 0.90 | CRBN (0.65) | CRBNNPC1MAPK13MAPK12MAPK11 | |
| Succinimide SCHEMBL8060686 | 0.90 | CRBN (0.65) | CRBNNPC1MAPK13MAPK12MAPK11 | |
| Succinimide SCHEMBL169754 | 0.90 | CRBN (0.65) | CRBNNPC1MAPK13MAPK12MAPK11 | |
| Succinimide SCHEMBL898832 | 0.87 | CRBN (0.61) | CRBNNPC1MAPK13MAPK12MAPK11 | |
| Succinimide SCHEMBL6823086 | 0.87 | CRBN (0.61) | CRBNNPC1MAPK13MAPK12MAPK11 | |
| Succinimide SCHEMBL1260852 | 0.87 | CRBN (0.69) | CRBNNPC1MAPK13MAPK12MAPK11 | |
| Succinimide SCHEMBL18397679 | 0.83 | CRBN (0.55) | CRBNNPC1MAPK13MAPK12MAPK11 | |
| Succinimide SCHEMBL73277 | 0.76 | CRBN (0.52) | CRBNNPC1MAPK13MAPK12MAPK11 | |
| Succinimide SCHEMBL25422802 | 0.76 | CRBN (0.46) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137199-A1 | ORGANIC TUNGSTEN COMPLEXES | R.T. Vanderbilt Company, Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008116099-A1 | ORGANIC TUNGSTEN COMPLEXES | R.T. VANDERBILT COMPANY, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234154-A1 | ORGANIC TUNGSTEN COMPLEXES | R.T. VANDERBILT COMPANY, INC. (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234154-A1 | ORGANIC TUNGSTEN COMPLEXES | DGAT2, DGAT1, DGKI | CRBN 4119/4885NPC1 3615/4885MAPK13 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.